Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

NEW YORK — Ubiquitous British actor Michael Byrne has died. The Shakespearean performer who appeared in films including "A Bridge Too Far," "Braveheart," "The Saint," "Harry Potter and the Deathly ...

Michael Byrne, the English actor familiar to fans of Indiana Jones and the Last Crusade, Harry Potter and the Deathly Hallows: Part 1, Braveheart, and such British TV series as Coronation Street and ...

Ubiquitous British actor Michael Byrne has died. The Shakespearean performer who appeared in films including “A Bridge Too Far,” “Braveheart,” “The Saint,” “Harry Potter and the Deathly Hallows” and ...

GOAL explains how fans can watch, stream, and follow the 2026 FIFA World Cup through YouTube and YouTube TV across the United States. Here, GOAL breaks down where to watch free live coverage, ...

IN ARIZONA AFTER A TEN MONTH LONG MANHUNT. THE TUOLUMNE COUNTY SHERIFF’S OFFICE HAS ARRESTED A MAN SUSPECTED IN A DEADLY SHOOTING IN SONORA. AUTHORITIES SAY 55 YEAR OLD TIMOTHY BOWLING SHOT AND KILLED ...

Attovia Therapeutics and Braveheart Bio revealed on Tuesday plans to go public, where they’ll aim to add to a recent upswing in big-ticket biotechnology stock offerings. Behind that prospect are two ...

After the Los Angeles Dodgers blowout loss to the Baltimore Orioles with a 12-1 score, the team now faces the Minnesota Twins on Monday in a new series with a familiar face. As the Dodgers brush off ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

HOUSTON -- The Twins will be without one of their key relievers for an extended period. Lefty Anthony Banda, who had emerged as one of manager Derek Shelton’s most trusted high-leverage options in ...

A late clinical-stage cardiovascular biotech focused on hypertrophic cardiomyopathy (HCM). The company is advancing a selective cardiac myosin inhibitor toward global Phase III development as a ...